The Study On The Therapy Effect Of Intracarotid Administration Of Human Cord Blood Mononuclear Cells On Vascular Dementia Rats

BackgroundThe mammalian neurons lack regeneration capacity. The repair of the injured central neural system (CNS) is very difficult. Recently, more and more studies focus their attention on cells transplantation for the therapy of brain and spinal cord disease. Fetal neural stem cells transplantation is one of the most effective method. However, transplantation of these cells is plagued with logistical, immunologic rejection and ethical considerations. After proliferated and induced in vitro, NSCs were isolated from bone marrow cells and differentiated into neurons and glial cells. Transplantation of bone marrow cells can treat disease of CNS, such as stroke and surgical trauma in brain. Compared with bone marrow, human umbilical cord blood has the advantage of weak immunogenicity, immature lympholeukocyte, low cytoactive of cell natural killer cell (NK), is easy to be collected and preserved, and isn't polluted by virus, bacterium and tumor cell, et al. Human umbilical cord blood contains more immature stem/progenitor cells than bone marrow. It shows that human umbilical cord blood may has more application value than bone marrow. It is reported that human cord blood mononuclear cells (HCMNCs) can proliferate multiply to appear cell clone, express nestin antigen and differentiate into nerves cells under certain conditions. Some researchers transplantated HCMNCs into animal models of CNS damage, such as stroke, surgical trauma and degencrative disease in brain and spinal cord. They observed neurological and behavior function recovery of animals. Vascular dementia (VD) is the damage of cognitive function. Cerebral infarction, low blood flow and haemorrhage are the reasons of the damage, which are caused by a series of cerebral vessels factors. Presently, VD has become the common and frequently encountered disease to influence health in middle-aged and aged people severitily. Incidence rate of VD rises year by year, but it hasn't effective method for treating it. Therefore, it is very important to carry out elementary and clinical research of intracarotid administration of HCMNCs treating the VD rats actively.